Role of IGF-I signaling in muscle bone interactions

Bikle, Daniel D.; Tahimic, Candice; Chang, Wenhan; Wang, Yongmei; Philippou, Αnastassios; Barton, Elisabeth R.

doi:10.1016/j.bone.2015.04.036

Cited by 136 publications

(96 citation statements)

References 153 publications

(147 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bearing in mind the above, our data suggesting an overexpression of IGF-1Ec by injured tissues, such as by the surrounding tissues in prostate cancer, is reminiscent of the preferential expression of IGF-1Ec post-skeletal muscle damage and that of the myocardium during the post-infarction period. [30][31][32][33][34][35][36] Interestingly, species-specific differences of hEc and mE actions may point to a possible different mode of actions at the receptor level. It has been reported that mE requires IGF-1R for its bioactivity, 36 while hEc appears to act in an IGF-1R independent manner.…”

Section: Discussionmentioning

confidence: 99%

The human Ec peptide: the active core of a progression growth factor with species-specific mode of action

Papageorgiou

Philippou

Armakolas

et al. 2016

Self Cite

View full text Add to dashboard Cite

ObJECTIvE: preferential IgF-1Ec expression has been firmly associated with skeletal muscle repair mechanisms, post-infarction remodeling of the myocardium, the pathophysiology of endometriosis and prostate cancer biology. Therefore, we have studied the possible biological significance of synthetic Ec peptide, a putative cleavage product of IgF-1Ec in pC-3 cells and C2C12 myoblasts. DESIgN: We had previously designed and synthesized commercially peptides corresponding to the human Ec and its mouse igf1 counterpart as well as synthetic peptides that correspond to parts of the hEc. Using proliferation and mitogenic signaling assays, we tested their effect on pC-3 cells and C2C12 myoblasts at different doses and in different culture conditions. RESUlTS: human Ec, hEc, was documented as exerting progression but not competence growth factor actions, activating ERK1/2 without affecting akt phosphorylation in pC-3 cells. a narrow concentration range of hEc (5-50nm) stimulated the growth of pC-3 cells grown in culture media supplemented with 10% FbS. hEc did not stimulate the growth of pC-3 cells cultured with media containing 0.5% FbS or in mouse C2C12 myoblasts under any culture conditions. The activity of hEc was blocked by a neutralizing anti-human IgF-1Ec antibody but not by a neutralizing anti-human IgF-1 receptor antibody. The synthetic mouse Ec was inactive in human pC-3 cells; however, it stimulated significantly the proliferation of mouse C2C12. by analyzing the bioactivity of synthetic hEc fragments, we documented that hEc's active core is located in the last 4aa of its C-terminal end. CONClUSION: The hEc peptide is an important progression factor for human pC-3 prostate cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

The human Ec peptide: the active core of a progression growth factor with species-specific mode of action

Papageorgiou

Philippou

Armakolas

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The liver is the major source of circulating IGF-1, producing approximately 75% of plasma IGF-1 (30). IGF-1 is also produced locally by bone cells such as osteoblasts, chondrocytes, osteo-clasts, and osteocytes, thereby functioning as an autocrine/ paracrine effector to regulate bone turnover (19,21,24,30,31). In addition, an inactive form of IGF-1 is stored within the bone matrix, and is activated and released during osteoclastmediated bone resorption (18).…”

Section: The Role Of Igf In Normal Bone Development and Remodelingmentioning

confidence: 99%

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis

Rieunier

Macaulay

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

Bone metastases are a frequent complication of cancer that are associated with considerable morbidity. Current treatments may temporarily palliate the symptoms of bone metastases but often fail to delay their progression. Bones provide a permissive environment because they are characterized by dynamic turnover, secreting factors required for bone maintenance but also stimulating the establishment and growth of metastases. Insulin-like growth factors (IGF) are the most abundant growth factors in bone and are required for normal skeletal development and function. Via activation of the IGF-1 receptors (IGF-1R) and variant insulin receptors, IGFs promote cancer progression, aggressiveness, and treatment resistance. Of specific relevance to bone biology, IGFs contribute to the homing, dormancy, colonization, and expansion of bone metastases. Furthermore, preclinical evidence suggests that tumor cells can be primed to metastasize to bone by a high IGF-1 environment in the primary tumor, suggesting that bone metastases may reflect IGF dependency. Therapeutic targeting of the IGF axis may therefore provide an effective method for treating bone metastases. Indeed, anti-IGF-1R antibodies, IGF-1R tyrosine kinase inhibitors, and anti-IGF-1/2 antibodies have demonstrated antitumor activity in preclinical models of prostate and breast cancer metastases, either alone or in combination with other agents. Several studies suggest that such treatments can inhibit bone metastases without affecting growth of the primary tumor. Although previous trials of anti-IGF-1R drugs have generated negative results in unselected patients, these considerations suggest that future clinical trials of IGF-targeted agents may be warranted in patients with bone metastases.

show abstract

“…IGF-1 has an essential role in the development of the growing skeleton and in the maintenance of bone mass during late adulthood and aging. 115 Its mitogenic action selectively promotes cell multiplication in young differentiated clones. 116 It can also stimulate tissue growth and has an important role in bone mass maintenance and acquisition.…”

Section: Gfs In Prpmentioning

confidence: 99%

Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering

2016

View full text Add to dashboard Cite

Presently, there is a high paucity of bone grafts in the United States and worldwide. Regenerating bone is of prime concern due to the current demand of bone grafts and the increasing number of diseases causing bone loss. Autogenous bone is the present gold standard of bone regeneration. However, disadvantages like donor site morbidity and its decreased availability limit its use. Even allografts and synthetic grafting materials have their own limitations. As certain specific stem cells can be directed to differentiate into an osteoblastic lineage in the presence of growth factors (GFs), it makes stem cells the ideal agents for bone regeneration. Furthermore, platelet-rich plasma (PRP), which can be easily isolated from whole blood, is often used for bone regeneration, wound healing and bone defect repair. When stem cells are combined with PRP in the presence of GFs, they are able to promote osteogenesis. This review provides in-depth knowledge regarding the use of stem cells and PRP in vitro, in vivo and their application in clinical studies in the future.

show abstract

Role of IGF-I signaling in muscle bone interactions

Cited by 136 publications

References 153 publications

The human Ec peptide: the active core of a progression growth factor with species-specific mode of action

The human Ec peptide: the active core of a progression growth factor with species-specific mode of action

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis

Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering

Contact Info

Product

Resources

About